Apellis Pharmaceuticals, Inc. (DELISTED) (APLS:DL)

41.03 0.00 (0.00%) USD  |  NASDAQ  |  May 22, 16:00
More

Apellis Pharmaceuticals Research and Development Expense (Annual) : 295.85M for Dec. 31, 2025

Research and Development Expense (Annual) Chart

View Research and Development Expense (Annual) for APLS:DL.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Annual) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Annual) Range, Past 5 Years

View Research and Development Expense (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Annual) Benchmarks

View Research and Development Expense (Annual) Benchmarks
Start Trial
Biogen, Inc. 1.481B
Eli Lilly & Co. 13.34B
Agios Pharmaceuticals, Inc. 334.36M
Spyre Therapeutics, Inc. 171.65M
Scholar Rock Holding Corp. 206.78M